Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Karenitecin in Relapsed or Refractory Non-small Cell Lung Cancer
NCT00010218Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2001
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of karenitecin in non-small cell lung cancer (NSCLC), sponsored by Cancer and Leukemia Group B. Started Apr 2001; status: completed.
02
Drugs
karenitecin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00010218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010218.